Compare InMode Ltd (INMD) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Medtronic PLC — how do they compare? InMode Ltd trades at $14.22 (market cap $809.93M), while Medtronic PLC trades at $88.79 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 138.6× InMode Ltd's market cap, and Medtronic PLC pays a 3.28% dividend while InMode Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and Medtronic PLC for 63 Days on average.
| INMD | MDT | |
|---|---|---|
Market Cap | $809.93M | $112.24B |
Volume | 365,490 | 105,663,236 |
Sector | Health | Health |
52-Week High | $16.62 | $105.35 |
52-Week Low | $12.76 | $73.75 |
Typical Hold Time | 28 Days | 63 Days |
Enterprise Value | $313.27M | $131.58B |
Dividend Yield | — | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.20, up 1.36% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with 76.52% gross margins and 20.69% net income margin, though Q1 2026 earnings missed expectations. Recent news includes product innovation with Morpheus8 Cool launch and an unsolicited acquisition offer from Steel Partners at $16.75 per share. Analyst consensus is divided with 45% buy ratings amid ongoing shareholder activism concerns.
The stock presents value opportunity with attractive valuation multiples (P/E 11.63, EV/EBITDA 4.48) but faces near-term execution risks. Key catalysts include Q3 earnings delivery and resolution of acquisition talks, while risks involve management credibility and competitive pressures in aesthetic medicine markets.
Medtronic (MDT) trades at $88.48, up 3.47% today, with a bullish analyst consensus and a $97.80 price target. The stock shows strong fundamentals with revenue growth to $33.54B in 2025 and a net income margin of 13.93%. Recent earnings beats and a 49-year dividend growth streak highlight operational strength, though technical indicators signal a near-term bearish trend with key support at $87.
MDT presents a compelling long-term investment with stable profitability and dividend reliability, but faces risks from debt increases and competitive pressures. Upside potential exists if the company maintains earnings momentum and executes on growth initiatives, while volatility may persist due to market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
